Free Trial
NASDAQ:UBX

UNITY Biotechnology Q3 2024 Earnings Report

UNITY Biotechnology logo
$0.18 -0.12 (-40.43%)
Closing price 07/8/2025
Extended Trading
$0.18 0.00 (0.00%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UNITY Biotechnology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

UNITY Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

UNITY Biotechnology Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Monday, November 4, 2024
Conference Call Time
12:00AM ET

Upcoming Earnings

UNITY Biotechnology's Q2 2025 earnings is scheduled for Tuesday, July 22, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

UNITY Biotechnology Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More UNITY Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like UNITY Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UNITY Biotechnology and other key companies, straight to your email.

About UNITY Biotechnology

UNITY Biotechnology (NASDAQ:UBX) is a clinical-stage biopharmaceutical company focused on the development of senolytic therapies designed to selectively eliminate senescent cells that contribute to a range of age-related diseases. Headquartered in South San Francisco, California, UNITY leverages cutting-edge cellular and molecular biology platforms to identify and prioritize targets involved in cellular senescence. The company’s proprietary R&D engine integrates transcriptomic, proteomic, and high-throughput screening data to advance programs through lead optimization and preclinical validation.

UNITY’s most advanced program, UBX1325, is a small-molecule inhibitor targeting the Bcl-xL protein and is being evaluated in clinical trials for the treatment of diabetic macular edema and other retinal diseases. Another pipeline asset, UBX0101, was investigated for osteoarthritis and served as an important proof of concept for the therapeutic potential of senolytics in degenerative joint disorders. The company’s portfolio further includes earlier-stage candidates aimed at idiopathic pulmonary fibrosis and other fibrotic conditions, reflecting a commitment to addressing indications driven by chronic inflammation and tissue remodeling.

Founded in 2011 by Dr. Nathaniel David and Antonio Olivas, UNITY Biotechnology has assembled a leadership team with deep expertise in drug discovery and development. Dr. David, a veteran of Genentech’s oncology research division, serves as Executive Chairman, while the senior management team includes veterans from leading pharmaceutical and biotech organizations. This blend of scientific rigor and strategic business acumen has enabled UNITY to forge collaborations, including an R&D partnership with Roche aimed at exploring senescence biology in oncology settings.

With research operations in both the United States and Europe, UNITY Biotechnology remains at the forefront of translational aging research. The company’s approach seeks not only to alleviate symptoms but to modify the underlying drivers of age-related pathologies, positioning its pipeline for potential applications across a broad spectrum of diseases with high unmet medical need.

View UNITY Biotechnology Profile

More Earnings Resources from MarketBeat